ClinicalTrials.gg
CompletedNCT03347110BE ACTIVE 2Updated Dec 1, 2023Results posted

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

A Phase 2 interventional study of Bimekizumab in Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 37 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Enrollment
9th of 14
184 · median 210
Started
2017
with 1 other
Phase 2
3 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 2, and was the 3rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Bimekizumab
  • Psoriatic Arthritis
  • PsA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the opinion of the Investigator, the subject is expected to benefit from participation in an Open Label Extension (OLE) study
  • Subject completed PA0008 without meeting any withdrawal criteria
  • Female subjects must be , permanently sterilized or, if of , must be willing to use a highly effective method of
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active

Exclusion criteria

Exclusion Criteria:

  • Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of IMP. Male subjects who are planning a partner pregnancy during the study or within 20 weeks following the last dose
  • Subjects with any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry
  • Subjects who meet any withdrawal criteria in PA0008. For any subject with an ongoing Serious Adverse Event, or a history of serious infections (including hospitalizations) in the lead-in study, the Medical Monitor must be consulted prior to the subject's entry into PA0009
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects will receive bimekizumab up to 2 years.

    Drug: Bimekizumab

Interventions

  • Bimekizumab at a prespecified dose.

    Also known as: UCB4940

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as events with onset date on or after the start date of study medication in PA0009.

    Time frame: From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120)

  2. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

    A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.

    Time frame: From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120)

Secondary outcomes

  1. Percentage of Participants Who Withdrew Due to Treatment-emergent Adverse Event (TEAE) During the Study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120)

  2. Percentage of Participants With American College of Rheumatology 20% Improvement (ACR20) Response at Week 48 Calculated Relative to Baseline of PA0008

    The ACR20 response rate was based on 20% or greater improvement relative to Baseline of PA0008 in the following measures: Tender Joint Count (TJC) based on 78 joints, Swollen Joint Count (SJC) based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by Patient's Global Assessment of Disease Activity (PGADA), Disease activity as assessed by Physician's Global Assessment of Disease Activity (PhGADA), Pain as assessed by Patient's Assessment of Arthritis Pain (PtAAP), Physical function as assessed by Health Assessment Questionnaire - Disability Index (HAQ-DI), Acute phase response as assessed by high sensitivity C-reactive protein (hs CRP). Participants for whom ACR could not be derived due to missing data were counted as non-responders as per NRI analysis.

    Time frame: Baseline of PA0008, Week 48

  3. Percentage of Participants With American College of Rheumatology 50% Improvement (ACR50) Response at Week 48 Calculated Relative to Baseline of PA0008

    The ACR50 response rate was based on 50% or greater improvement relative to Baseline of PA0008 in the following measures: TJC based on 78 joints, SJC based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by PGADA, Disease activity as assessed by PhGADA, Pain as assessed by PtAAP, Physical function as assessed by HAQ-DI, Acute phase response as assessed by hs CRP. Participants for whom ACR could not be derived due to missing data were counted as non-responders as per NRI analysis.

    Time frame: Baseline of PA0008, Week 48

  4. Percentage of Participants With American College of Rheumatology 70% Improvement (ACR70) Response at Week 48 Calculated Relative to Baseline of PA0008

    The ACR70 response rate was based on 70% or greater improvement relative to Baseline of PA0008 in the following measures: TJC based on 78 joints, SJC based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by PGADA, Disease activity as assessed by PhGADA, Pain as assessed by PtAAP, Physical function as assessed by HAQ-DI, Acute phase response as assessed by hs CRP. Participants for whom ACR could not be derived due to missing data were counted as non-responders as per NRI analysis.

    Time frame: Baseline of PA0008, Week 48

  5. Change From Baseline of PA0008 in Maastricht Ankylosing Spondylitis Enthesitis Index (MASES) at Week 48 Calculated Relative to Baseline of PA0008

    The MASES is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process). Each item was scored as 0 = not tender or 1 = tender and then were summed for a possible score of 0 to 13, with higher scores indicating worse enthesitis. If 7 or more items were available, MASES was calculated by dividing the summed score with the number of assessments and multiplying the result by 13. If less than 7 items were available, MASES was treated as missing.

    Time frame: Baseline of PA0008, Week 48

  6. Change From Baseline of PA0008 in the Leeds Dactylitis Index (LDI) at Week 48 Calculated Relative to Baseline of PA0008

    Presence of dactylitis was assessed using the LDI basic which evaluated for a greater than or equal to (\>=) 10% difference in the circumference of the digit compared to the opposite digit and was then multiplied by the tenderness score, using a simple grading system (0=absent, 1=present). The results from each digit with dactylitis were summed to produce a final score. For the final score, the minimum value for LDI is zero and there is no maximum value. A low score indicates less dactylitis symptoms. A score of zero is considered dactylitis free. Observed values have been reported in this outcome measure.

    Time frame: Baseline of PA0008, Week 48

  7. Percentage of Participants With Psoriasis Area Severity Index (PASI75) Response at Week 48 Calculated Relative to Baseline of PA0008

    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline of PA0008. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with psoriasis (PSO) for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. For the Final score, minimum possible PASI value is 0= no disease, maximum value is 72= maximal disease. Missing PASI responses were imputed using least observation carried forward (LOCF) for any visits where the corresponding BSA has not increased compared to the preceding visit.

    Time frame: Baseline of PA0008, Week 48

  8. Percentage of Participants With Psoriasis Area Severity Index (PASI90) Response at Week 48 Calculated Relative to Baseline of PA0008

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline of PA0008. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. For the final score, minimum possible PASI value is 0= no disease, maximum value is 72= maximal disease. Missing PASI responses were imputed using LOCF for any visits where the corresponding BSA has not increased compared to the preceding visit.

    Time frame: Baseline of PA0008, Week 48

07

Results

Posted Dec 1, 2023

Participant flow

The study started to enroll study participants in November 2017 and concluded in October 2020.

Participant flow — Overall Study
MilestoneBimekizumab 160 mg
Started183
Completed161
Not completed22
Withdrew: Other (participant is incarcerated)1
Withdrew: Withdrawal by subject9
Withdrew: Lost to follow-up1
Withdrew: Lack of efficacy2
Withdrew: Adverse event, non-fatal9

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as events with onset date on or after the start date of study medication in PA0009.

Time frame:
From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsBimekizumab 160 mg (SS)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study80.9
PrimaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.

Time frame:
From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
percentage of participantsBimekizumab 160 mg (SS)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study7.7
SecondaryPercentage of Participants Who Withdrew Due to Treatment-emergent Adverse Event (TEAE) During the Study

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120)
Reported as:
Number · percentage of participants
Percentage of Participants Who Withdrew Due to Treatment-emergent Adverse Event (TEAE) During the Study
percentage of participantsBimekizumab 160 mg (SS)
Percentage of Participants Who Withdrew Due to Treatment-emergent Adverse Event (TEAE) During the Study4.9
SecondaryPercentage of Participants With American College of Rheumatology 20% Improvement (ACR20) Response at Week 48 Calculated Relative to Baseline of PA0008

The ACR20 response rate was based on 20% or greater improvement relative to Baseline of PA0008 in the following measures: Tender Joint Count (TJC) based on 78 joints, Swollen Joint Count (SJC) based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by Patient's Global Assessment of Disease Activity (PGADA), Disease activity as assessed by Physician's Global Assessment of Disease Activity (PhGADA), Pain as assessed by Patient's Assessment of Arthritis Pain (PtAAP), Physical function as assessed by Health Assessment Questionnaire - Disability Index (HAQ-DI), Acute phase response as assessed by high sensitivity C-reactive protein (hs CRP). Participants for whom ACR could not be derived due to missing data were counted as non-responders as per NRI analysis.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 20% Improvement (ACR20) Response at Week 48 Calculated Relative to Baseline of PA0008
percentage of participantsBimekizumab 160 mg (FAS)
Percentage of Participants With American College of Rheumatology 20% Improvement (ACR20) Response at Week 48 Calculated Relative to Baseline of PA000879.0
SecondaryPercentage of Participants With American College of Rheumatology 50% Improvement (ACR50) Response at Week 48 Calculated Relative to Baseline of PA0008

The ACR50 response rate was based on 50% or greater improvement relative to Baseline of PA0008 in the following measures: TJC based on 78 joints, SJC based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by PGADA, Disease activity as assessed by PhGADA, Pain as assessed by PtAAP, Physical function as assessed by HAQ-DI, Acute phase response as assessed by hs CRP. Participants for whom ACR could not be derived due to missing data were counted as non-responders as per NRI analysis.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 50% Improvement (ACR50) Response at Week 48 Calculated Relative to Baseline of PA0008
percentage of participantsBimekizumab 160 mg (FAS)
Percentage of Participants With American College of Rheumatology 50% Improvement (ACR50) Response at Week 48 Calculated Relative to Baseline of PA000864.6
SecondaryPercentage of Participants With American College of Rheumatology 70% Improvement (ACR70) Response at Week 48 Calculated Relative to Baseline of PA0008

The ACR70 response rate was based on 70% or greater improvement relative to Baseline of PA0008 in the following measures: TJC based on 78 joints, SJC based on 76 joints; 3 of the 5 remaining core set measures: Disease activity as assessed by PGADA, Disease activity as assessed by PhGADA, Pain as assessed by PtAAP, Physical function as assessed by HAQ-DI, Acute phase response as assessed by hs CRP. Participants for whom ACR could not be derived due to missing data were counted as non-responders as per NRI analysis.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 70% Improvement (ACR70) Response at Week 48 Calculated Relative to Baseline of PA0008
percentage of participantsBimekizumab 160 mg (FAS)
Percentage of Participants With American College of Rheumatology 70% Improvement (ACR70) Response at Week 48 Calculated Relative to Baseline of PA000847.5
SecondaryChange From Baseline of PA0008 in Maastricht Ankylosing Spondylitis Enthesitis Index (MASES) at Week 48 Calculated Relative to Baseline of PA0008

The MASES is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process). Each item was scored as 0 = not tender or 1 = tender and then were summed for a possible score of 0 to 13, with higher scores indicating worse enthesitis. If 7 or more items were available, MASES was calculated by dividing the summed score with the number of assessments and multiplying the result by 13. If less than 7 items were available, MASES was treated as missing.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Mean · score on a scale
Change From Baseline of PA0008 in Maastricht Ankylosing Spondylitis Enthesitis Index (MASES) at Week 48 Calculated Relative to Baseline of PA0008
score on a scaleBimekizumab 160 mg (FAS)
Change From Baseline of PA0008 in Maastricht Ankylosing Spondylitis Enthesitis Index (MASES) at Week 48 Calculated Relative to Baseline of PA0008-2.99 ± 0.33
SecondaryChange From Baseline of PA0008 in the Leeds Dactylitis Index (LDI) at Week 48 Calculated Relative to Baseline of PA0008

Presence of dactylitis was assessed using the LDI basic which evaluated for a greater than or equal to (\>=) 10% difference in the circumference of the digit compared to the opposite digit and was then multiplied by the tenderness score, using a simple grading system (0=absent, 1=present). The results from each digit with dactylitis were summed to produce a final score. For the final score, the minimum value for LDI is zero and there is no maximum value. A low score indicates less dactylitis symptoms. A score of zero is considered dactylitis free. Observed values have been reported in this outcome measure.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Mean · score on a scale
Change From Baseline of PA0008 in the Leeds Dactylitis Index (LDI) at Week 48 Calculated Relative to Baseline of PA0008
score on a scaleBimekizumab 160 mg (FAS)
Change From Baseline of PA0008 in the Leeds Dactylitis Index (LDI) at Week 48 Calculated Relative to Baseline of PA0008-54.31 ± 67.09
SecondaryPercentage of Participants With Psoriasis Area Severity Index (PASI75) Response at Week 48 Calculated Relative to Baseline of PA0008

The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline of PA0008. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with psoriasis (PSO) for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. For the Final score, minimum possible PASI value is 0= no disease, maximum value is 72= maximal disease. Missing PASI responses were imputed using least observation carried forward (LOCF) for any visits where the corresponding BSA has not increased compared to the preceding visit.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area Severity Index (PASI75) Response at Week 48 Calculated Relative to Baseline of PA0008
percentage of participantsBimekizumab 160 mg (FAS)
Percentage of Participants With Psoriasis Area Severity Index (PASI75) Response at Week 48 Calculated Relative to Baseline of PA000890.0
SecondaryPercentage of Participants With Psoriasis Area Severity Index (PASI90) Response at Week 48 Calculated Relative to Baseline of PA0008

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline of PA0008. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. For the final score, minimum possible PASI value is 0= no disease, maximum value is 72= maximal disease. Missing PASI responses were imputed using LOCF for any visits where the corresponding BSA has not increased compared to the preceding visit.

Time frame:
Baseline of PA0008, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area Severity Index (PASI90) Response at Week 48 Calculated Relative to Baseline of PA0008
percentage of participantsBimekizumab 160 mg (FAS)
Percentage of Participants With Psoriasis Area Severity Index (PASI90) Response at Week 48 Calculated Relative to Baseline of PA000880.0

Adverse events

Collected over From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab 160 mg (SS)0/183 (0%)14/183 (7.7%)82/183 (44.8%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBimekizumab 160 mg (SS)
CholelithiasisHepatobiliary disorders2/183
Foot deformityMusculoskeletal and connective tissue disorders2/183
Anal fistulaGastrointestinal disorders1/183
Inguinal herniaGastrointestinal disorders1/183
Umbilical herniaGastrointestinal disorders1/183
Chronic sinusitisInfections and infestations1/183
Meniscus injuryInjury, poisoning and procedural complications1/183
Ligament ruptureInjury, poisoning and procedural complications1/183
OsteochondrosisMusculoskeletal and connective tissue disorders1/183
Pregnancy on contraceptivePregnancy, puerperium and perinatal conditions1/183
Most frequent other events
Most frequent other events
EventBimekizumab 160 mg (SS)
Upper respiratory tract infectionInfections and infestations20/183
NasopharyngitisInfections and infestations19/183
PsoriasisSkin and subcutaneous tissue disorders14/183
Oral candidiasisInfections and infestations13/183
Psoriatic arthropathyMusculoskeletal and connective tissue disorders12/183
BronchitisInfections and infestations11/183
PharyngitisInfections and infestations10/183
SinusitisInfections and infestations10/183

Baseline characteristics

Baseline Characteristics refer to SS which consisted of all study participants who had given informed consent for PA0009 and had received at least one dose of study medication in PA0009.

Age, Categorical
Age, Categorical(Participants)Bimekizumab 160 mg (SS)
<=18 years0
Between 18 and 65 years165
>=65 years18
Age, Continuous
Age, Continuous(years)Bimekizumab 160 mg (SS)
Mean49.0 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab 160 mg (SS)
Female87
Male96
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab 160 mg (SS)
Black4
White179
08

Study locations

37 sites
  • Pa0009 025
    Lexington, Kentucky 40504, United States
  • Pa0009 003
    Hagerstown, Maryland 21502, United States
  • Pa0009 011
    Lansing, Michigan 48910, United States
  • Pa0009 028
    Rochester, New York 14642, United States
  • Pa0009 014
    Portland, Oregon 97239, United States
  • Pa0009 001
    Duncansville, Pennsylvania 16635, United States
  • Pa0009 012
    Johnston, Rhode Island 02919, United States
  • Pa0009 004
    Charleston, South Carolina 29406, United States
  • Pa0009 010
    Jackson, Tennessee 38305, United States
  • Pa0009 006
    Dallas, Texas 75231, United States
  • Pa0009 013
    Mesquite, Texas 75150, United States
  • Pa0009 205
    Brno, Czechia
  • Pa0009 207
    Olomouc, Czechia
  • Pa0009 210
    Praha 11, Czechia
  • Pa0009 201
    Praha 4, Czechia
  • Pa0009 202
    Praha, Czechia
  • Pa0009 203
    Zlín, Czechia
  • Pa0009 302
    Cologne, Germany
  • Pa0009 309
    Erlangen, Germany
  • Pa0009 304
    Hamburg, Germany
  • Pa0009 301
    Ratingen, Germany
  • Pa0009 403
    Budapest, Hungary
  • Pa0009 401
    Veszprém, Hungary
  • Pa0009 452
    Bialystok, Poland
  • Pa0009 453
    Elbląg, Poland
  • Pa0009 456
    Elbląg, Poland
  • Pa0009 455
    Kraków, Poland
  • Pa0009 451
    Poznań, Poland
  • Pa0009 450
    Toruń, Poland
  • Pa0009 454
    Warsaw, Poland
  • Pa0009 459
    Warsaw, Poland
  • Pa0009 465
    Wrocław, Poland
  • Pa0009 604
    Moscow, Russian Federation
  • Pa0009 605
    Moscow, Russian Federation
  • Pa0009 607
    Moscow, Russian Federation
  • Pa0009 606
    Saint Petersburg, Russian Federation
  • Pa0009 608
    Saint Petersburg, Russian Federation
09

References and documents

Publications

  • Mease PJ, Asahina A, Gladman DD, Tanaka Y, Tillett W, Ink B, Assudani D, de la Loge C, Coarse J, Eells J, Gossec L. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology (Oxford). 2023 Feb 1;62(2):617-628. doi: 10.1093/rheumatology/keac353. PubMed 35789257 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2020, 35 months.

Results were first posted in Dec 2023, 3 years 1 month after primary completion. A results delay was requested in Oct 2021.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2017
First posted
Nov 20, 2017
StartActual
Nov 22, 2017
Primary completionActual
Oct 29, 2020
CompletionActual
Oct 29, 2020
Results delay requested
Oct 28, 2021
Results first posted
Dec 1, 2023
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03347110
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Nov 22, 2017
Primary completion
Oct 29, 2020
Completion
Oct 29, 2020
Results posted
Dec 1, 2023
Last update
Dec 1, 2023

Study contacts

UCB Cares
study director · +1 8445992273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion